Chronic Myelogenous Leukemia - virtual training

Quiz for Session 3

Please complete the Quiz.

Question 1- About the discontinuation rates in the ENESTnd study:
A
At 5 years, twice as many imatinib patients had discontinued as compared to the nilotinib 300 mg BID arm

B
Rates of discontinuation were higher after the second year of treatment

C
The most frequent cause for discontinuation was progression of disease

Question 2- True or False. In the ENESTnd trial, progression in the imatinib arm was approximately 5 times higher than in the nilotinib arm
A
True

B
False


Thank you for completing the quiz.


Evolution of CML treatment and goals of therapy in 2014:
  • 2nd Gen TKIs in front line setting
  • Benefit of switch from imatinib to nilotinib (ENESTcmr)
  • Potential for discontinuation on imatinib (STOP 2G)
  • Planned and ongoing discontinuation trials (ENESTop)

Dr. Gianantonio Rosti

Department of Hematology and Oncology
'L. and A. Seràgnoli' St Orsola University Hospital - Bologna

View Session Back